MXPA05010214A - Sistemas de sintasa de poliquetida pufa y uso de los mismos. - Google Patents

Sistemas de sintasa de poliquetida pufa y uso de los mismos.

Info

Publication number
MXPA05010214A
MXPA05010214A MXPA05010214A MXPA05010214A MXPA05010214A MX PA05010214 A MXPA05010214 A MX PA05010214A MX PA05010214 A MXPA05010214 A MX PA05010214A MX PA05010214 A MXPA05010214 A MX PA05010214A MX PA05010214 A MXPA05010214 A MX PA05010214A
Authority
MX
Mexico
Prior art keywords
systems
pufa
polyketide synthase
pufa pks
nucleic acid
Prior art date
Application number
MXPA05010214A
Other languages
English (en)
Inventor
James H Flatt
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Publication of MXPA05010214A publication Critical patent/MXPA05010214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)

Abstract

La presente invencion se refiere generalmente a sistemas (PKS) de cintaza de poliquetida (PUFA) de acido graso poliunsaturado, a homologos de los mismos, a moleculas aisladas de acido nucleido y moleculas recombinantes de acido nucleico que codifican los dominios activos, tales como un sistema PUFA PKS, a organismos modificados geneticamente que comprenden sistemas PUFA PKS, a metodos de elaboracion y el uso de dichos sistemas para la produccion de moleculas bioactivas de interes y a metodos novedosos para identificar nuevos microorganismos bacterianos y no bacterianos que tienen dicho sistema PUFA PKS.
MXPA05010214A 2003-03-26 2004-03-26 Sistemas de sintasa de poliquetida pufa y uso de los mismos. MXPA05010214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45797903P 2003-03-26 2003-03-26
PCT/US2004/009323 WO2004087879A2 (en) 2003-03-26 2004-03-26 Pufa polyketide synthase systems and uses thereof

Publications (1)

Publication Number Publication Date
MXPA05010214A true MXPA05010214A (es) 2005-12-14

Family

ID=33131738

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011000195A MX341785B (es) 2003-03-26 2004-03-26 Sistemas de sintasa de poliquetida pufa y uso de los mismos.
MXPA05010214A MXPA05010214A (es) 2003-03-26 2004-03-26 Sistemas de sintasa de poliquetida pufa y uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011000195A MX341785B (es) 2003-03-26 2004-03-26 Sistemas de sintasa de poliquetida pufa y uso de los mismos.

Country Status (12)

Country Link
EP (1) EP1623008B1 (es)
JP (3) JP2007524377A (es)
KR (3) KR101234198B1 (es)
CN (1) CN101389213B (es)
AU (2) AU2004225485B2 (es)
BR (1) BRPI0409046A (es)
CA (1) CA2520396C (es)
ES (1) ES2516641T3 (es)
HK (1) HK1088632A1 (es)
IL (1) IL200625A0 (es)
MX (2) MX341785B (es)
WO (1) WO2004087879A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6566583B1 (en) 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US7247461B2 (en) 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
US7217856B2 (en) 1999-01-14 2007-05-15 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7211418B2 (en) 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
WO2001054510A1 (en) 2000-01-28 2001-08-02 Omegatech, Inc. Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors
BRPI0613295A2 (pt) 2005-07-01 2010-12-28 Martek Biosciences Corp produto oleoso contendo ácido graxo poliinsaturado e usos e produção do mesmo
GB0603160D0 (en) 2006-02-16 2006-03-29 Rothamsted Res Ltd Nucleic acid
AU2007226510B2 (en) 2006-03-15 2013-09-19 Dsm Ip Assets B.V. Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems
EP2061347A2 (en) * 2006-08-29 2009-05-27 Martek Biosciences Corporation USE OF DPA(n-6) OILS IN INFANT FORMULA
CA2754409A1 (en) * 2009-03-04 2010-09-10 University Of Miyazaki Method for determining fatty acid synthetic pathway of microorganism, and pcr primer set for use in the method
ES2752196T3 (es) * 2009-03-16 2020-04-03 Dsm Ip Assets Bv Producción de proteínas en microorganismos del filo Labyrinthulomycota
WO2010108114A2 (en) 2009-03-19 2010-09-23 Martek Biosciences Corporation Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof
EP2614829A1 (en) 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
KR101570771B1 (ko) 2013-11-18 2015-11-23 대한민국 고도불포화지방산 생합성을 위한 재조합 벡터 및 이를 이용하여 제작된 형질전환 식물체
JP6682109B2 (ja) * 2015-01-09 2020-04-15 国立大学法人 宮崎大学 ヤブレツボカビ類を用いたリグニン分解活性を有するタンパク質の製造方法
KR102442450B1 (ko) 2016-05-12 2022-09-14 디에스엠 아이피 어셋츠 비.브이. 미세조류에서 오메가-3 다중불포화 지방산 생산을 증가시키는 방법
JP7540943B2 (ja) * 2018-08-10 2024-08-27 協和発酵バイオ株式会社 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法
CN112601808A (zh) * 2018-08-10 2021-04-02 协和发酵生化株式会社 生产二十碳五烯酸的微生物和二十碳五烯酸的制造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6566583B1 (en) * 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
IL133272A0 (en) * 1997-06-04 2001-04-30 Calgene Llc Production of polyunsaturated fatty acid by expression of polyketide-like synthesis genes in plants
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US7247461B2 (en) * 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
ES2343106T3 (es) * 2000-09-28 2010-07-23 BIORIGINAL FOOD & SCIENCE CORP. Fad4, fad5, fad5-2 y fad6, miembros de la familia de desaturasas de acidos grasos y usos de los mismos.
TWI337619B (en) * 2001-04-16 2011-02-21 Martek Biosciences Corp Pufa polyketide synthase systems and uses thereof
AU2002302247A1 (en) * 2001-05-21 2002-12-03 Ecopia Biosciences Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures

Also Published As

Publication number Publication date
EP1623008A2 (en) 2006-02-08
JP2016000048A (ja) 2016-01-07
CA2520396A1 (en) 2004-10-14
AU2008249169A1 (en) 2008-12-11
CN101389213A (zh) 2009-03-18
JP2007524377A (ja) 2007-08-30
KR20120123726A (ko) 2012-11-09
EP1623008A4 (en) 2009-05-27
WO2004087879A2 (en) 2004-10-14
BRPI0409046A (pt) 2006-04-18
KR101234200B1 (ko) 2013-02-19
ES2516641T3 (es) 2014-10-31
KR101234199B1 (ko) 2013-02-20
HK1088632A1 (en) 2006-11-10
EP1623008B1 (en) 2014-07-30
AU2004225485B2 (en) 2008-08-21
JP5890791B2 (ja) 2016-03-22
WO2004087879A3 (en) 2008-07-24
AU2004225485A1 (en) 2004-10-14
KR101234198B1 (ko) 2013-02-19
IL200625A0 (en) 2011-07-31
JP6134361B2 (ja) 2017-05-24
AU2008249169B2 (en) 2012-03-15
KR20120097502A (ko) 2012-09-04
CN101389213B (zh) 2014-05-28
KR20060006014A (ko) 2006-01-18
JP2013143945A (ja) 2013-07-25
MX341785B (es) 2016-09-01
CA2520396C (en) 2016-08-09

Similar Documents

Publication Publication Date Title
WO2002083870A3 (en) Pufa polyketide synthase systems and uses thereof
MXPA05010214A (es) Sistemas de sintasa de poliquetida pufa y uso de los mismos.
MX2007004502A (es) Sistemas de policetido de sintasa de ??cido graso poliinsaturado pufa y usos de los mismos.
WO2006135866A3 (en) Pufa polyketide synthase systems and uses thereof
BRPI0410681A (pt) moléculas de ácido nucléico isoladas, polipeptìdio, gene quimérico, célula hospedeira transformada, métodos para a produção de ácido linoléico e de ácidos graxos w-3, método para modular a biosìntese de ácidos graxos w-3 ou w-6, óleo microbial, e métodos para a obtenção de uma molécula de ácido nucléico
AU2002321165A1 (en) Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced pfkb gene
AU2002235933A1 (en) Process for the production of l-amino acids using strains of the family enterobacteriaceae that contain an attenuated acea gene
EP0994190A3 (en) DNA conferring L-homoserine resistance to bacteria, and its use
AU2002321094A1 (en) A novel group of alpha-amylases and a method for identification and production of novel alpha-amylases
ID29136A (id) Suatu proses untuk pembuatan asam karboksilat kiral dari nitril dengan menggunakan suatu nitrilase atau mikroorganisme yang terdiri dari suatu gen untuk nitrilase
ATE330022T1 (de) Verfahren zur herstellung einer zielsubstanz durch fermentation
FR2804971B1 (fr) Adn codant une acetohydroxyacide synthase, bacterie le contenant et procede de production de l-valine par culture de cette bacterie
AU2003238717A1 (en) POLYPEPTIDES HAVING Alpha- H-Alpha-AMINO ACID AMIDE RACEMASE ACTIVITY AND NUCLEIC ACIDS ENCODING THE SAME
WO2003038106A3 (en) A process for the production of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced fadr or iclr gene
WO2002031155A3 (en) Gene cluster for ramoplanin biosynthesis
DE602005019421D1 (de) Grosstechnisch geeigneter mikroorganismus
AU2002312930A1 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
WO2003029476A3 (en) Process for the preparation of d-pantothenic acid and/or its salts
WO2003040291A3 (de) Gene die für kohlenstoffmetabolismus- und energieproduktion-proteine codieren
TH127943A (th) ระบบการสังเคราะห์โพลีคีไทด์ของกรดไขมันไม่อิ่มตัวที่มีหลายโมเลกุลต่อกัน และประโยชน์ใช้งานของสารดังกล่าว
EP1472347A4 (en) INCREASING PROTEIN EXPRESSION IN BACILLUS SUBTILIS
AU2002342763A1 (en) Process for the preparation of non-aromatic l-amino acids using strains of the enterobacteriaceae family
TH127943B (th) ระบบการสังเคราะห์โพลีคีไทด์ของกรดไขมันไม่อิ่มตัวที่มีหลายโมเลกุลต่อกัน และประโยชน์ใช้งานของสารดังกล่าว

Legal Events

Date Code Title Description
FG Grant or registration